Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Neuroblastoma

NCT00003513 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped slow accrual

Conditions

Neuroblastoma

Interventions

DRUG: Antineoplaston therapy (Atengenal + Astugenal)

Sponsor

Burzynski Research Institute